Announcement on behalf of Amaran of not Distributing Dividends of 2023
1.Date of the board of directors resolution:2024/04/12 2.Type and monetary amount of dividend distribution:The Board of Directors of Amaran resolved not to distribute dividends of 2023. 3.Any other matters that …
Announcement on behalf of Amaran that the BOD resolved to convene the 2024 Annual General Shareholders’ Meeting
1.Date of the board of directors resolution:2024/04/12 2.General shareholders’ meeting date:2024/05/27 3.General shareholders’ meeting location: 5th Floor, No.19, Shengyi 5th Rd., Zhubei City, Hsinchu County 4.Cause for convening the meeting …
Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform
Title: OBI-992, a novel TROP2 targeting antibody-drug conjugate, displayed excellent antitumor efficacy in various animal models Abstract presentation number: 1893 / Poster number 23/4 PDF LINK Title: In vitro …
Announcement on behalf of OBIGEN of not Distributing Dividends of 2023
1.Date of the board of directors resolution:2024/03/20 2.Type and monetary amount of dividend distribution:The Board of Directors of OBIGEN resolved not to distribute dividends of 2023. 3.Any other matters that …
Announcement on behalf of OBIGEN that the BOD resolved to issue 2024 employee stock options and the subscription rules.
1.Date of the board of directors resolution:2024/03/20 2.Issue period:Issued within two years since the date of approval of Board of Directors; issued at once or in tranches depending on actual …
Announcement on behalf of OBIGEN that the BOD resolved to convene the 2024 Annual General Shareholders’ Meeting
1.Date of the board of directors resolution:2024/03/20 2.General shareholders’ meeting date:2024/06/19 3.General shareholders’ meeting location: Conference room of OBI Pharma, Inc. (6th Floor, No. 508, Section 7, Zhongxiao East Road, …
OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform.
Poster Presentations to highlight the latest research on OBI-992 (anti-TROP2 ADC) and OBI’s novel GlycOBI ADC platform. OBI Pharma, Inc. (TPEx: 4174) today announced preclinical data for OBI-992, a potential …
OBI Pharma to present the Study Results of OBI-992 at the 14th World ADC London
OBI Pharma is excited to announce that Dr. Ming-Tain Lai, Chief Scientific Officer, has been invited to present an oral presentation at the upcoming 14th World ADC conference in London, United Kingdom. This …
OBI announces the termination of OBI-3424 Phase II trial
Following a strategic portfolio review, the Board of Directors of OBI Pharma, Inc. (4174) has decided to terminate the OBI-3424-001 trial today (March 11, 2024), while continuing the collaboration of …
Announcement of BOD’s resolution to lift the non-competition restrictions for managerial officers
1.Date of the board of directors resolution:2024/03/11 2.Name and title of the managerial officer with permission to engage in competitive conduct: Heidi Wang/ CEO Ming-Tain Lai/ Chief Scientific Officer Colin …